stella
beta
Hypofractionated Radiotherapy Combined With NALIRIF, PD-1 Antibody in Locally Recurrent Rectal Cancer(NOVELTY-R) — Stella
Recruiting
Back to Locally Recurrent Rectal Cancer trials
Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.
Trial locations
(1 site)
China
Fudan University Shanghai Cancer Center, Shanghai, Shanghai Municipality
View full record on ClinicalTrials.gov